302.1 Results of MMF+EVO combination in drug switching after kidney transplantation.
Dr. Ebru Sevinc Ok, Turkey
302.2 Comparison of actual versus ideal body weight based dosing of anti-thymocyte globulin in kidney transplant recipients
Andrew Santeusanio, United States
302.4 CYP3A5 Polymorphism in Kidney Transplantation: Individualizing Tacrolimus Dosing
Dr. Sushrut Gupta, India
302.6 Atypical cervical cytology in solid organ transplantation patients: 20 years of experience in a single center
Dr. Tugba Tekelioglu, Turkey
302.7 High intra patient variability (IPV) of serum tacrolimus is associated with a worsening serum creatinine in tkidney transplant patients attening Inkosi Albert Luthuli Central Hospital, Durban, South Africa.
Dr. Mahomed Ismail Haffejee, South Africa
302.8 Correlating Tacrolimus Levels with Dose Formulation: Implications for Toxicity and Renal Graft Rejection in a cohort of kidney Transplant Recipients with Steroid-free maintenance immunosuppression.
Dr. Sergio DJ. Salcedo Herrera Sr., Colombia
302.9 Identification of cytokine profiles in blood samples from kidney transplant recipients